KR20060123567A - 허혈성 조직의 관류를 자극하기 위한 인자 ⅹⅲ의 용도 - Google Patents
허혈성 조직의 관류를 자극하기 위한 인자 ⅹⅲ의 용도 Download PDFInfo
- Publication number
- KR20060123567A KR20060123567A KR1020067016616A KR20067016616A KR20060123567A KR 20060123567 A KR20060123567 A KR 20060123567A KR 1020067016616 A KR1020067016616 A KR 1020067016616A KR 20067016616 A KR20067016616 A KR 20067016616A KR 20060123567 A KR20060123567 A KR 20060123567A
- Authority
- KR
- South Korea
- Prior art keywords
- fxiii
- factor xiii
- fxiiia
- ischemic
- perfusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000000302 ischemic effect Effects 0.000 title claims description 12
- 108010071289 Factor XIII Proteins 0.000 title claims description 10
- 229940012444 factor xiii Drugs 0.000 title claims description 10
- 230000010412 perfusion Effects 0.000 title claims description 5
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 238000009472 formulation Methods 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 210000004204 blood vessel Anatomy 0.000 claims description 17
- 230000002792 vascular Effects 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 4
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 230000004089 microcirculation Effects 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 6
- 230000000903 blocking effect Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 abstract description 5
- 230000008081 blood perfusion Effects 0.000 abstract description 4
- 230000001052 transient effect Effects 0.000 abstract description 4
- 230000033115 angiogenesis Effects 0.000 description 16
- 210000004087 cornea Anatomy 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 108090000190 Thrombin Proteins 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 108010082117 matrigel Proteins 0.000 description 8
- 229960004072 thrombin Drugs 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- 238000011813 knockout mouse model Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 230000001023 pro-angiogenic effect Effects 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 3
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 3
- 102000007614 Thrombospondin 1 Human genes 0.000 description 3
- 108010046722 Thrombospondin 1 Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- 108060008539 Transglutaminase Proteins 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 102000003601 transglutaminase Human genes 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000007998 vessel formation Effects 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 1
- 108010000196 Factor XIIIa Proteins 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000032692 embryo implantation Effects 0.000 description 1
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04003950.5 | 2004-02-20 | ||
| EP04003950A EP1566183A1 (en) | 2004-02-20 | 2004-02-20 | Use of factor XIII for stimulating the perfusion of ischemic tissue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060123567A true KR20060123567A (ko) | 2006-12-01 |
Family
ID=34707356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067016616A Ceased KR20060123567A (ko) | 2004-02-20 | 2005-02-15 | 허혈성 조직의 관류를 자극하기 위한 인자 ⅹⅲ의 용도 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070167361A1 (https=) |
| EP (2) | EP1566183A1 (https=) |
| JP (1) | JP2007523111A (https=) |
| KR (1) | KR20060123567A (https=) |
| AT (1) | ATE429244T1 (https=) |
| AU (1) | AU2005215114B2 (https=) |
| CA (1) | CA2556805C (https=) |
| DE (1) | DE602005014085D1 (https=) |
| DK (1) | DK1718328T3 (https=) |
| ES (1) | ES2325996T3 (https=) |
| WO (1) | WO2005079839A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITTO20130532A1 (it) * | 2013-06-27 | 2014-12-28 | Donato Gemmati | Nuovo biomarcatore prognostico nell'infarto acuto del miocardio |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69431430T2 (de) * | 1993-03-30 | 2003-05-22 | Hoechst Japan Ltd., Tokio/Tokyo | Faktor XIII zur Behandlung von Hautwunden |
| AU7483798A (en) * | 1997-05-14 | 1998-12-08 | Zymogenetics Inc. | Use of factor xiii for the manufacture of a medicament for the treatment of reperfusion injury and mucosal damage |
| EP1572168B1 (en) * | 2002-02-06 | 2010-05-26 | Vicor Technologies, Inc. | Anti-infarction molecules |
-
2004
- 2004-02-20 EP EP04003950A patent/EP1566183A1/en not_active Withdrawn
-
2005
- 2005-02-15 AT AT05715335T patent/ATE429244T1/de active
- 2005-02-15 DK DK05715335T patent/DK1718328T3/da active
- 2005-02-15 AU AU2005215114A patent/AU2005215114B2/en not_active Ceased
- 2005-02-15 KR KR1020067016616A patent/KR20060123567A/ko not_active Ceased
- 2005-02-15 JP JP2006553508A patent/JP2007523111A/ja active Pending
- 2005-02-15 DE DE602005014085T patent/DE602005014085D1/de not_active Expired - Lifetime
- 2005-02-15 WO PCT/EP2005/001495 patent/WO2005079839A1/en not_active Ceased
- 2005-02-15 US US10/589,957 patent/US20070167361A1/en not_active Abandoned
- 2005-02-15 ES ES05715335T patent/ES2325996T3/es not_active Expired - Lifetime
- 2005-02-15 CA CA2556805A patent/CA2556805C/en not_active Expired - Fee Related
- 2005-02-15 EP EP05715335A patent/EP1718328B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ATE429244T1 (de) | 2009-05-15 |
| CA2556805C (en) | 2013-04-02 |
| EP1718328A1 (en) | 2006-11-08 |
| AU2005215114B2 (en) | 2010-05-20 |
| EP1566183A1 (en) | 2005-08-24 |
| DK1718328T3 (da) | 2009-07-27 |
| WO2005079839A1 (en) | 2005-09-01 |
| DE602005014085D1 (de) | 2009-06-04 |
| US20070167361A1 (en) | 2007-07-19 |
| EP1718328B1 (en) | 2009-04-22 |
| ES2325996T3 (es) | 2009-09-28 |
| JP2007523111A (ja) | 2007-08-16 |
| AU2005215114A1 (en) | 2005-09-01 |
| CA2556805A1 (en) | 2005-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6247692B2 (ja) | 皮膚瘢痕を治療する組成物及び方法 | |
| PT1779862E (pt) | Eritropoietina em doses sub-policitémicas para o tratamento de diabetes | |
| US20070093748A1 (en) | Methods and systems for treating injured cardiac tissue | |
| JP5400006B2 (ja) | 虚血性疾患の予防または治療剤 | |
| JP3012319B2 (ja) | 脳及び筋肉組織傷害による浮腫の治療剤 | |
| WO2017152039A1 (en) | Protection and delivery of multiple therapeutic proteins | |
| EP0724884B1 (en) | Side effect inhibitor for cancer therapy | |
| CN116270715B (zh) | Otud5在制备防治心肌缺血再灌注损伤药物中的应用 | |
| JPWO1997035609A1 (ja) | 組織因子凝固系インヒビター含有血管新生阻害剤 | |
| KR20060123567A (ko) | 허혈성 조직의 관류를 자극하기 위한 인자 ⅹⅲ의 용도 | |
| RU2301667C1 (ru) | Способ лечения заболеваний различной этиологии и травм различных органов | |
| US8106009B2 (en) | Pharmaceutical composition for preventing or treating ischemic diseases | |
| Berlanga | Heberprot-P: experimental background and pharmacological bases | |
| RU2729788C2 (ru) | Средство, его применение и способ повышения устойчивости организма млекопитающих к ишемически-реперфузионному поражению тонкого кишечника | |
| US7691371B2 (en) | Preparation comprising batroxobin for inhibiting local invasion of malignant tumors | |
| RU2288738C2 (ru) | Способ экспериментальной терапии инфаркта миокарда | |
| AU2003200309B2 (en) | Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases | |
| Hens et al. | Catecholamine secreting tumor of the glomus jugulare | |
| KR100847979B1 (ko) | 바트록소빈을 함유하는 악성종양 국소 침윤억제제 | |
| CN121472138A (zh) | 一种多功能干细胞外泌物及其制备方法和应用 | |
| McGinnigle et al. | 191 Role of mir-214 in angiotensin ii induced hypertensive heart disease | |
| EP1495766A1 (en) | Factor VII activating protease (FSAP) derived polypeptides for the treatment of angiogenesis-related disorders | |
| AU8272887A (en) | Method for inducing endogenous production of tissue plasminogen activator (tpa) | |
| Rastegar | Protection against ischaemia and reperfusion-induced ventricular arrhythmias: role of bradykinin | |
| HK1106142B (en) | Malignant tumor local infiltration inhibitor containing batroxobin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20060818 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| G170 | Re-publication after modification of scope of protection [patent] | ||
| PG1701 | Publication of correction | ||
| A201 | Request for examination | ||
| AMND | Amendment | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20100126 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20110831 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20120830 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20110831 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20121130 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20120830 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20131216 Appeal identifier: 2012101010141 Request date: 20121130 |
|
| AMND | Amendment | ||
| PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20121228 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20121130 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20120229 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20100126 Patent event code: PB09011R02I |
|
| B601 | Maintenance of original decision after re-examination before a trial | ||
| PB0601 | Maintenance of original decision after re-examination before a trial |
Comment text: Report of Result of Re-examination before a Trial Patent event code: PB06011S01D Patent event date: 20130204 |
|
| J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20121130 Effective date: 20131216 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20131216 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20121130 Decision date: 20131216 Appeal identifier: 2012101010141 |